Expert Interview
Looking at ESMO 2025 Data on Next-Generation ADCs for Platinum-Resistant Ovarian Cancer from Tubulis (TUB-040) & Merck (R-DXd)
Ticker(s): MRK, TubulisInstitution: Kaiser Permanente
- Gynecologic Oncologist at Kaiser Permanente Riverside Medical Center (CA)
- Treats 10+ ovarian cancer patients annually
- Clinical interest in ovarian cancer and very familiar with investigational agents in gynecologic oncology
How do you view the clinical relevance of the efficacy signals seen with TUB-040 and R-DXd in platinum-resistant ovarian cancer compared with existing options such as mirvetuximab soravtansine or standard chemotherapy?
Added By: sara_adminGiven that TUB-040 targets NaPi2b while R-DXd targets a different antigen, how important do you think target selection and linker technology are for advancing ADC efficacy and safety in this setting?
Added By: sara_adminWhat do these data suggest about the broader evolution of ADCs in gynecologic malignancies, and are there particular combinations or biomarkers you believe could further optimize outcomes in PROC?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
